

## Supplementary materials

### **Vagal innervation limits brain injury by inhibiting gut-selective integrin-mediated intestinal immunocyte migration in intracerebral hemorrhage**


Peiji Fu<sup>1,2,3#</sup>, Yan Zong<sup>1,2,3#</sup>, Yinming Dai<sup>1,2#</sup>, Li Zhu<sup>1,2</sup>, Shuai Chen<sup>1,2,3</sup>, Yousef Rastegar-Kashkooli<sup>4</sup>, Junmin Wang<sup>4\*</sup>, Jiewen Zhang<sup>1\*</sup>, Jian Wang<sup>4\*</sup>, Chao Jiang<sup>1,2,3\*</sup>

<sup>1</sup>Department of Neurology, The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital, 450003, Zhengzhou, P. R. China;

<sup>2</sup>Department of Neurology, The Fifth Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, P. R. China; <sup>3</sup>The Laboratory of Cerebrovascular Diseases and Neuroimmunology, The Fifth Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, P. R. China; <sup>4</sup>Department of Human Anatomy,

School of Basic Medical Sciences, Zhengzhou University, 450001, Zhengzhou, P. R. China.

1 **Supplementary Figures and legends**




2

3 **Figure S1. Establishment of a subdiaphragmatic vagotomy (SDV) mouse**  
 4 **model and photoconversion of KikGR mice.**

5 **A)** To establish the mouse subdiaphragmatic vagotomy (SDV), we isolated the  
 6 ventral and dorsal branches of the vagus nerve. **B)** After SDV, 24-h food intake  
 7 increased on day 8 compared to sham vagotomy, as determined by the two-  
 8 tailed paired t-test.  $n = 5$  mice per group.  $**P < 0.01$ . **C)** During the  
 9 photoconversion process in KikGR mice, we exposed the MLNs while covering

1 the surrounding tissues with aluminum foil to prevent additional irradiation. **D)**  
2 The MLNs showed green fluorescence (KikG) before and red fluorescence  
3 (KikR) after photoconversion. **E)** We created a schematic diagram to illustrate  
4 the SDV research in WT mice conducted in this study. We induced ICH in WT  
5 mice 20 d after SDV; we then evaluated the neuroinflammation, intestinal  
6 immunocyte trafficking, brain injury severity, and neurologic deficits in WT mice  
7 that underwent SDV.  
8




1

2 **Figure S2. Dynamic changes in green fluorescence detected with an *in***  
 3 ***vivo* imaging system in KikGR mice experienced SDV, photoconversion,**  
 4 **and ICH.**

5 **A-C)** We measured the green (KikG) fluorescence intensity of KikGR mice in  
 6 various parts of their bodies at different time points. The first measurements  
 7 occurred before photoconversion, immediately before ICH (4 d after  
 8 photoconversion), and 3 d after ICH (7 d after photoconversion). *n* = 5 mice per  
 9 group. **D-F)** The 2<sup>nd</sup> set of measurements took place on the heads of the same  
 10 mice during the same time points. **G-J)** We took the 3<sup>rd</sup> set of measurements in  
 11 the freshly isolated brain, dCLNs, MLNs, and brain sections of the same mice

1 3 d after ICH.  $n=5$  mice per group. The average intensity of green (KikG)  
2 fluorescence was calculated and analyzed for statistical significance using a  
3 two-tailed paired t-test or a two-tailed Mann-Whitney U test, as appropriate. The  
4 results indicated no statistical difference in the green (KikG) fluorescence  
5 intensity between the various time points or body parts being measured.

6




**Figure S3. Dynamic changes in individual NDS tests, body weight, and rectal temperature of ICH mice previously underwent SDV or sham vagotomy.**

**A)** During a 28-day research period, individual NDS tests were performed on ICH mice that had undergone a sham vagotomy or SDV.  $n = 10$  mice per group. Generalized estimation equations were used, followed by the two-tailed Mann-Whitney U test. However, no significant differences were found. **B)** Similarly, changes in body weight and rectal body temperature were monitored in ICH mice throughout the research period, and we performed the analysis with repeated measures ANOVA of the results. However, no significant differences were found between mice that had undergone a sham vagotomy or SDV.  $n =$

1 10 mice per group.

2




1

2 **Figure S4. Representative gating strategies for cells isolated from the**  
 3 **brain and peripheral blood concerning the effects of α7nAChR agonists**  
 4 **on previous SDV in ICH.**

5 **A) Representative gating strategies used to detect α4β7 integrin and CD103 in**



1 the populations of CD45<sup>high</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells  
2 isolated from the brain 3 d after ICH. **B)** Representative gating strategies used  
3 to detect  $\alpha 4\beta 7$  integrin and CD103 in the populations of CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>,  
4 CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells in peripheral blood 3 d after ICH.  
5




1

2 **Figure S5. Representative gating strategies of cells isolated from MLNs**  
 3 **and Peyer's patches concerning the effects of α7nAChR agonists on**  
 4 **previous SDV in ICH.**

5 **A) Representative gating strategies used to detect α4β7 integrin and CD103 in**

1 the populations of CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells  
2 isolated from the MLNs 3 d after ICH. **B)** Representative gating strategies used  
3 to detect  $\alpha 4\beta 7$  integrin and CD103 in the populations of CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>,  
4 CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells isolated from Peyer's patches 3 d after  
5 ICH.  
6




1

2 **Figure S6. Negative findings on the reversible effects of α7nAChR**  
 3 **agonists on intestinal immunocyte homing and retention detected by flow**  
 4 **cytometry after SDV in the acute phase of ICH.**

5 **A)** The influence of previous SDV or previous SDV supplied with α7nAChR  
 6 agonist treatment on the proportions of CD103-positive CD45<sup>high</sup>, CD3<sup>+</sup>, and  
 7 CD3CD8<sup>+</sup> cells in the hemorrhagic brain 3 d after ICH. *n* = 6 mice per group.

8 The Kruskal-Wallis test was performed. **B)** The ratios of CD8<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup>  
 9 cells to CD45<sup>+</sup> cells in the peripheral blood 3 d after ICH. *n* = 6 mice per group.

1 The Kruskal-Wallis test was performed. **C)** Percentage changes of CD103-  
2 positive CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells in the  
3 peripheral blood 3 d after ICH. *n* = 6 mice per group. One-way ANOVA with  
4 Bonferroni correction for CD103-positive CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, and CD3<sup>+</sup>CD4<sup>+</sup>  
5 cells, while the Kruskal-Wallis test for others was performed. **D)** Proportional  
6 changes of  $\alpha$ 4 $\beta$ 7 integrin-positive CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells  
7 in the peripheral blood 3 d after ICH. *n* = 6 mice per group. The Kruskal-Wallis  
8 test for  $\alpha$ 4 $\beta$ 7 integrin-positive CD3<sup>+</sup>CD4<sup>+</sup>, while one-way ANOVA with  
9 Bonferroni correction for  $\alpha$ 4 $\beta$ 7 integrin-positive CD45<sup>+</sup>, CD8<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup>  
10 cells was performed. **E)** The proportions of CD103-positive CD45<sup>+</sup>, CD3<sup>+</sup>, and  
11 CD8<sup>+</sup> cells in the MLNs 3 d after ICH. *n*=6 mice per group. The Kruskal-Wallis  
12 test was performed. **F)** The percentages of CD4<sup>+</sup>, CD8<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells  
13 to CD45<sup>+</sup> cells in the Peyer's patches 3 d after ICH. The Kruskal-Wallis test was  
14 performed. **G)** The ratios of  $\alpha$ 4 $\beta$ 7 integrin-positive CD8<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells in  
15 Peyer's patches 3 d after ICH. *n* = 6 mice per group. The Kruskal-Wallis test  
16 was performed. **H)** The percentages of CD103-positive CD4<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup>  
17 cells in Peyer's patches 3 d after ICH. *n* = 6 mice per group. One-way ANOVA  
18 with Bonferroni correction was performed. The percentages of the cell  
19 subpopulations indicated in this figure were not influenced by previous SDV or  
20 previous SDV combined with  $\alpha$ 7nAChR agonists.  
21




1

2 **Figure S7. Representative gating strategies for cells isolated from the**  
 3 **brain and peripheral blood concerning the effects of  $\alpha 7$ nAChR agonists**  
 4 **on  $\beta 7$  integrin antagonists in ICH.**

5 **A) A representative flow cytometric gating strategy for  $\alpha 4\beta 7$  integrin and CD103**

1 in the populations of CD45<sup>high</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells  
2 accumulated to the hemorrhagic brain 3 d after ICH. **B)** The flow cytometry  
3 correlation strategies used for  $\alpha$ 4 $\beta$ 7 integrin and CD103 in the populations of  
4 CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells in peripheral blood  
5 3 d after ICH.  
6



1


2 **Figure S8. Representative gating strategies of cells isolated from MLNs**

3 **and Peyer's patches concerning the effects of  $\alpha 7$ nAChR agonists on  $\beta 7$**

4 **integrin antagonists in ICH.**



1 **A)** The gating strategies for  $\alpha 4\beta 7$  integrin and CD103 in the populations of  
2 CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells isolated from the  
3 MLNs 3 d after ICH. **B)** Representative flow cytometric gating strategies for  
4  $\alpha 4\beta 7$  integrin and CD103 in the populations of CD45<sup>+</sup>, CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>,  
5 CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells isolated from Peyer's patches 3 d after ICH.  
6




1

2 **Figure S9. Negative findings on the effects of β7 integrin antagonists on**  
 3 **intestinal immunocyte homing and retention detected by flow cytometry**  
 4 **in ICH.**

5 **A)** Analysis for the influence of β7 integrin antagonists or β7 integrin  
 6 antagonists combined with α7nAChR agonists on the infiltration of CD4<sup>+</sup> cells  
 7 in the brain lesions 3 d after ICH. *n* = 6 mice per group. The Kruskal-Wallis test  
 8 was performed. **B)** Proportional changes of α4β7 integrin-positive CD45<sup>high</sup> and  
 9 CD3<sup>+</sup>CD8<sup>+</sup> cells in the hemorrhagic brain 3 d after ICH. *n* = 6 mice per group.

1 One-way ANOVA with Bonferroni correction for CD45<sup>high</sup> cells and the Kruskal-  
2 Wallis test for CD3<sup>+</sup>CD8<sup>+</sup> cells were performed. **C)** The percentages of CD103-  
3 positive CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells in the  
4 bloodstream 3 d after ICH. *n* = 6 mice per group. The Kruskal-Wallis test was  
5 performed. **D)** The proportions of CD4<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> cells to CD45<sup>+</sup> cells in  
6 the MLNs 3 d after ICH. *n* = 6 mice per group. One-way ANOVA with Bonferroni  
7 correction for CD4<sup>+</sup> cells and the Kruskal-Wallis test for CD3<sup>+</sup>CD4<sup>+</sup> cells were  
8 performed. **E)** Percentage changes of  $\alpha 4\beta 7$  integrin-positive CD8<sup>+</sup> and  
9 CD3<sup>+</sup>CD8<sup>+</sup> cells in the MLNs 3 d after ICH. *n* = 6 mice per group. The Kruskal-  
10 Wallis test was performed. **F)** Proportional changes of CD103-positive CD4<sup>+</sup>  
11 and CD3<sup>+</sup>CD4<sup>+</sup> cells in the MLNs 3 d after ICH. *n* = 6 mice per group. The  
12 Kruskal-Wallis test was performed. **G)** The percentage of CD3<sup>+</sup>CD8<sup>+</sup> cells to  
13 CD45<sup>+</sup> cells in the Peyer's patches 3 d after ICH. *n* = 6 mice per group. The  
14 Kruskal-Wallis test was performed. **H)** Ratios of  $\alpha 4\beta 7$  integrin-positive CD3<sup>+</sup>,  
15 CD8<sup>+</sup>, and CD3<sup>+</sup>CD8<sup>+</sup> cells in the Peyer's patches 3 d after ICH. *n* = 6 mice per  
16 group. One-way ANOVA with Bonferroni correction for multiple comparisons  
17 was performed. **I)** The percentages of CD103-positive CD4<sup>+</sup>, CD8<sup>+</sup>, and  
18 CD3<sup>+</sup>CD8<sup>+</sup> cells in the Peyer's patches 3 d post-ICH. *n* = 6 mice per group. The  
19 Kruskal-Wallis test was performed. Neither  $\beta 7$  integrin antagonists nor  $\beta 7$   
20 integrin antagonists combined with  $\alpha 7nAChR$  agonists have influence on the  
21 cell subpopulations mentioned above.



1

2 **Figure S10. Dynamic changes in individual NDS tests, body weight, and**  
 3 **rectal temperature of ICH mice received vehicle or  $\beta$ 7 integrin antagonists.**

4 **A)** Individual NDS tests on days 1, 3, 7, 14, and 28 after ICH.  $n=10$  mice per  
 5 group. Generalized estimation equations were performed, followed by two-  
 6 tailed Mann-Whitney U tests.  $*P < 0.05$ ,  $**P < 0.01$ . **B-C)** Changes in body  
 7 weight and rectal temperatures at multiple time points during the 28-d research  
 8 period.  $n=10$  mice per group. Generalized estimation equations were performed,  
 9 followed by two-tailed Mann-Whitney U tests. The results did not show  
 10 significant differences.